Nanox Signs U.S. Distribution Deal with Radiology Oncology Systems for Nanox.ARC
Nanox Impact has inked a U.S. distribution deal with Radiology Oncology Systems to deploy its FDA-cleared Nanox.ARC tomosynthesis systems across hospitals and oncology clinics nationwide. The agreement leverages ROS’s service network to support rollouts of low-cost, reduced-dose 3D imaging at additional clinical sites.
1. Distribution Agreement Details
Nanox Impact Inc. has entered a U.S. distribution agreement with Radiology Oncology Systems to supply Nanox.ARC systems to hospitals and oncology clinics nationwide. The deal outlines deployments leveraging ROS’s service infrastructure to support initial rollouts and system maintenance across multiple clinical sites.
2. Nanox.ARC System Features
The Nanox.ARC is an FDA-cleared digital tomosynthesis device that delivers 3D imaging at a lower cost and reduced radiation dose compared to traditional CT scanners. Its multi-source X-ray configuration enables broader clinical adoption by simplifying workflow and minimizing operational expenses.
3. Radiology Oncology Systems’ Role
Radiology Oncology Systems will utilize its 25-year track record in diagnostic imaging and oncology equipment to manage equipment distribution, installation, and service support. Their established relationships with U.S. hospitals and clinics aim to accelerate Nanox.ARC adoption in both traditional and oncology-adjacent care settings.
4. Strategic Commercial Expansion
This partnership represents a key step in Nanox’s channel partner strategy, diversifying its U.S. distribution network to drive commercial execution. By systematically expanding its footprint through targeted agreements, Nanox seeks to enhance market penetration and lay the groundwork for future revenue growth.